Carly Levine is an Associate at the AMR Action Fund (AMRAF), where she has helped guide numerous investments into biotech companies that are developing therapeutics or diagnostics for priority drug-resistant pathogens. Prior to joining AMRAF, she spent nearly a decade in academia, where she developed a deep understanding of the biology of drug resistance and the science that underpins novel antimicrobial development. Dr. Levine holds additional Board of Director positions at Adaptive Phage Therapeutics, Venatorx Pharmaceuticals, BioVersys AG, and Pattern Bioscience.
